Products

OptiKey

Communicate and control your computer using your eyes

optikey.org Source★ 86GPL-3.0Utilities / System Utilities

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Free
No monthly subscription pricing
Launched
11y ago
2015-09-16 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    Full computer control and speech with your eyes

    Sep 16, 2015 · 11y agoLaunch page

Open Source & Self-Hosting

GitHub · MCP / Skill
Last commit 2026-09-14
GitHub Stars
★ 86
Forks
8
License
GPL-3.0
Primary language
Go

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Direct39%
  • Organic Search31%
  • Referrals10%
  • Social6%
  • Other13%

Countries

  • United States100%

Search

Domain authority —Domain registered 2015-01-16

KeywordMonthly volume
optikey930
eye mouse cursor490
optikeyo60

Traffic data: Vaneform

Pricing

Website does not list public plan prices.

Trial: None · Observed 2026-11-05 · Source page

Pages & changes

Tracked since 2015-09-16

Key pages

Weekly snapshots
Home
optikey.org/ Snapshot 2026-11-06

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does OptiKey get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is OptiKey and what platforms does it support?
OptiKey is catalogued under System Utilities: Communicate and control your computer using your eyes. Supported platforms: Web.
Is OptiKey open source?
OptiKey has a public repository (https://github.com/OptiKey/OptiKey) under the GPL-3.0 license, recording 86 GitHub stars.Source

Related products in this category

Utilities / System Utilities

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.